Responder Rates to Fampridine Differ between Clinical Subgroups of Ms Patients and Patient Reported Outcome Influences Treatment Decision Making

ConclusionResponder rates and treatment continuation of fampridine differed between clinical subgroups of MS. PROs influenced treatment decision making of fampridine in clinical practice, particularly in patients with mild ambulatory impairment or those reporting UEF impairment. To some extent, these findings explain discrepancies found between clinical trials and clinical practice, and support the importance of subgroup analyses and incorporation of PROs in clinical trials. For clinical practice, using PROs to assess patients experience in conjunction with performance measures helps in treatment decision making.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research